SCHEMBL1332207

SCHEMBL1332207

O=C(O)COc1ccc(Cl)cc1[N+](=O)[O-]

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.64
▸ KMT2A Q03164 4/20 0.64
▸ MEN1 O00255 3/20 0.64
▸ TDP1 Q9NUW8 2/20 0.62
▸ ALDH1A1 P00352 4/20 0.60
▸ SMN1; SMN2 Q16637 3/20 0.60
▸ NPC1 O15118 1/20 0.60
▸ RAB9A P51151 1/20 0.60
▸ MAPT P10636 6/20 0.57
▸ TSHR P16473 1/20 0.56
▸ LMNA P02545 3/20 0.56
▸ MAPK1 P28482 2/20 0.56
▸ PTGDR2 Q9Y5Y4 5/20 0.55
▸ HPGD P15428 2/20 0.55
▸ TP53 P04637 1/20 0.55
▸ PTGDR Q13258 4/20 0.55
▸ HTT P42858 1/20 0.55
▸ FAAH O00519 1/20 0.54
▸ BCHE P06276 1/20 0.54
▸ ACHE P22303 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9722784 0.88 KDM4E (0.64) KDM4EKMT2AMEN1TDP1ALDH1A1
SCHEMBL11380309 0.87 KDM4E (0.63) KDM4EKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL11380305 0.87 KDM4E (0.63) KDM4EKMT2AMEN1TDP1ALDH1A1
SCHEMBL6327826 0.85 ALDH1A1 (0.71) KDM4EKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL10788762 0.83 MEN1 (0.66) KDM4EKMT2AMEN1TDP1ALDH1A1
SCHEMBL27634054 0.82 S1PR4 (0.56) KDM4EKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL27634048 0.82 S1PR4 (0.56) KDM4EKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL4186418 0.82 MEN1 (0.64) KDM4EKMT2AMEN1TDP1ALDH1A1
SCHEMBL10508964 0.82 MEN1 (0.64) KDM4EKMT2AMEN1ALDH1A1MAPT
SCHEMBL2599653 0.82 MEN1 (0.64) KDM4EKMT2AMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394986-B2 Phenoxiacetic acid derivatives ASTRAZENECA AB (GB) 2013-03-12 — — US disclosed
US-20110281898-A1 PHENOXIACETIC ACID DERIVATIVES ASTRAZENECA AB 2011-11-17 — — US disclosed
US-8003703-B2 Phenoxiacetic acid derivatives ASTRAZENECA AB (SE) 2011-08-23 — — US disclosed
EP-1660431-B1 PHENOXYACETIC ACID DERIVATIVES ASTRAZENECA AB (SE) 2009-04-01 — — EP disclosed
US-20060293352-A1 Phenoxiacetic acid derivatives ASTRAZENECA AB (SE) 2006-12-28 — — US disclosed
EP-1660431-A2 PHENOXYACETIC ACID DERIVATIVES Astrazeneca AB (SE) 2006-05-31 — — EP disclosed
WO-2005018529-A2 PHENOXIACETIC ACID DERIVATIVES ASTRAZENECA AB (SE) 2005-03-03 — — WO disclosed
US-4252952-A 7-(α-Substituted glycinamido)-3-substituted methyl-3-cephem-4-carboxylic acids and their derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-02-24 — — US disclosed
US-4178445-A 7-(α-Substituted glycinamido)-3-substituted methyl-3-cephem-4-carboxylic acids and their derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1979-12-11 — — US disclosed
US-4039536-A 7-(α-SUBSTITUTED GLYCINAMIDO)-3-SUBSTITUTED METHYL-3-CEPHEM-4-CARBOXYLIC ACIDS AND THEIR DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1977-08-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293352-A1 Phenoxiacetic acid derivatives HRH2, HRH1, HCAR2 KDM4E 1701/4885KMT2A 647/4885MEN1 3996/4885
US-20110281898-A1 PHENOXIACETIC ACID DERIVATIVES HIF1A, HPD, HIF1AN KDM4E 608/4885KMT2A 607/4885MEN1 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback